16156-01-7

Upstream product

• 201415-38-5 5-phenylbenzoxazole 
• 104-87-0 4-methyl-benzaldehyde 
• 1134-36-7 2-amino-4-phenylphenol 
• 352-32-9 p-fluorotoluene 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 99-94-5 p-Toluic acid 

Downstream Products

• 16143-05-8 5-phenyl-2-(4-styryl-phenyl)-benzooxazole 
• 59098-25-8 2-{4-[2-(5-methyl-2-phenyl-2H-[1,2,3]triazol-4-yl)-vinyl]-phenyl}-5-phenyl-benzooxazole 
• 52596-46-0 2-{4-[4-(5-phenyl-benzooxazol-2-yl)-trans-styryl]-phenyl}-2H-benzo[1,2,3]triazole 
• 59098-40-7 2-(4-{2-[2-(4-chloro-phenyl)-5-methyl-2H-[1,2,3]triazol-4-yl]-vinyl}-phenyl)-5-phenyl-benzooxazole 
• 59098-45-2 2-{4-[2-(2,5-diphenyl-2H-[1,2,3]triazol-4-yl)-vinyl]-phenyl}-5-phenyl-benzooxazole 
• 65203-96-5 2-{4-[4-(5-chloro-2-phenyl-2H-[1,2,3]triazol-4-yl)-styryl]-phenyl}-5-phenyl-benzooxazole 
• 65204-21-9 2-{4-[4-(4-chloro-5-phenyl-[1,2,3]triazol-2-yl)-styryl]-phenyl}-5-phenyl-benzooxazole 
• 59099-41-1 4-(5-phenyl-benzoxazol-2-yl)-4'-(2-phenyl-2H-1,2,3-triazol-4-yl)-stilbene 
• 71943-98-1 2-(4-{4-[4,5-dichloro-1-(4-chloro-phenyl)-1H-pyrazol-3-yl]-styryl}-phenyl)-5-phenyl-benzooxazole 
• 71943-92-5 2-(4-{4-[4-chloro-1-(4-chloro-phenyl)-1H-pyrazol-3-yl]-styryl}-phenyl)-5-phenyl-benzooxazole 
• 71943-85-6 2-(4-{4-[1-(4-chloro-phenyl)-1H-pyrazol-3-yl]-styryl}-phenyl)-5-phenyl-benzooxazole 
• 71943-90-3 2-{4-[4-(4-chloro-1-phenyl-1H-pyrazol-3-yl)-styryl]-phenyl}-5-phenyl-benzooxazole 
• 71943-77-6 5-phenyl-2-{4-[4-(1-phenyl-1H-pyrazol-3-yl)-styryl]-phenyl}-benzooxazole 
• 71944-05-3 2-{4-[4-(1,5-diphenyl-1H-pyrazol-3-yl)-styryl]-phenyl}-5-phenyl-benzooxazole 

Relevant academic research and scientific papers

Direct oxidative C-H arylation of benzoxazoles with arylsulfonyl hydrazides promoted by palladium complexes

This study describes a direct oxidative C-2 arylation of benzoxazoles using arylsulfonyl hydrazides as the aryl sources. A simple catalyst system [Pd(OAc)2 and Ph3P] allows the reactions to proceed smoothly under oxidative reaction conditions. Other heteroarenes such as caffeine and benzothiazole are also applicable substrates. Notably, this catalytic system tolerates halogen substituents which provides a useful complement to the current cross-coupling reactions which use aryl halides. Georg Thieme Verlag KG Stuttgart · New York.

Ni-Catalyzed C?F Bond Functionalization of Unactivated Aryl Fluorides and Corresponding Coupling with Oxazoles

A Ni-catalyzed C?F bond functionalization of unactivated aryl fluorides with oxazoles as coupling partners was developed. Various arylated oxazoles could be obtained in moderate to good yields in the presence of Ni(cod)2/IMes catalytic system.

Iodine-mediated arylation of benzoxazoles with aldehydes

A simple and efficient methodology for the arylation of benzoxazoles with aldehydes using iodine as the mediator has been developed. The reaction proceeded smoothly with a range of substrates to give the corresponding arylated products in moderate to good yields.

Direct oxidative C-H arylation of benzoxazoles with arylsulfonyl hydrazides promoted by palladium complexes

This study describes a direct oxidative C-2 arylation of benzoxazoles using arylsulfonyl hydrazides as the aryl sources. A simple catalyst system [Pd(OAc)2 and Ph3P] allows the reactions to proceed smoothly under oxidative reaction conditions. Other heteroarenes such as caffeine and benzothiazole are also applicable substrates. Notably, this catalytic system tolerates halogen substituents which provides a useful complement to the current cross-coupling reactions which use aryl halides.

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.